New: Introducing the Finviz Futures Map

Crinetics Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Crinetics Pharmaceuticals, Inc.

Aug-21	Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) CRNX GlobeNewswire
Aug-11	Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Aug-07	Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update CRNX GlobeNewswire
Jul-13	Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025 CRNX GlobeNewswire
Jul-11	Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 CRNX GlobeNewswire
Jul-10	Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
Jun-30	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline CRNX GlobeNewswire
Jun-16	Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 CRNX GlobeNewswire
Jun-10	Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
May-23	Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 CRNX GlobeNewswire
May-15	Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 CRNX GlobeNewswire
May-12	Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CRNX GlobeNewswire
May-08	Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update CRNX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.